Opinion: It’s ethical to test promising coronavirus vaccines against less-promising ones

Nir Eyal () and Marc Lipsitch
Additional contact information
Nir Eyal: Center for Population-Level Bioethics and Department of Philosophy, LipsitchRutgers University, New Brunswick, NJ 08901; Department of Health Behavior, Society, and Policy, Rutgers School of Public Health, Piscataway, NJ 08854
Marc Lipsitch: Center for Communicable Disease Dynamics, Department of Epidemiology, and Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115N.E. declares no competing interest. M.L. receives research support from Pfizer, unrelated to COVID-19

Proceedings of the National Academy of Sciences, 2020, vol. 117, issue 32, 18898-18901

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.pnas.org/content/117/32/18898.full (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nas:journl:v:117:y:2020:p:18898-18901

Access Statistics for this article

More articles in Proceedings of the National Academy of Sciences from Proceedings of the National Academy of Sciences
Bibliographic data for series maintained by PNAS Product Team ().